Study of ADCT-402 in Patients With Relapsed or Refractory B-cell Lineage Acute Lymphoblastic Leukemia (B-ALL)
Status:
Terminated
Trial end date:
2018-07-03
Target enrollment:
Participant gender:
Summary
This study evaluates ADCT-402 in participants with relapsed or refractory B-cell lineage
acute lymphoblastic leukemia (B-ALL). Participants will participate in a dose-escalation
phase (Part 1) and dose expansion (Part 2). In Part 2, participants will receive the dose
level identified in Part 1.